Role of serum pro-hepcidin and GSTM1 and GSTT1 null polymorphisms for estimation of the risk of myocardial siderosis in children and young adults" with β-thalassemia major"

被引：4
作者：
Chakarov I. [1 ]
Vlaykova T. [2 ]
Slavov E. [3 ]
Marinov R. [4 ]
Chakarova P. [1 ]
机构：
[1] Department of Pediatrics, Trakia University, Stara Zagora
[2] Department of Chemistry and Biochemistry, Trakia University, Stara Zagora, 6000
[3] Department of Molecular Biology, Immunology and Medical Genetics, Trakia University, Stara Zagora
[4] Clinic of Pediatrics, National Center of Heart Diseases, Sofia
来源：
Comparative Clinical Pathology | 2014年 / 23卷 / 3期
关键词：
Gene polymorphisms; GSTM1; GSTT1; Hepcidin; Iron overload; β-thalassemia;
D O I：
10.1007/s00580-013-1677-9
中图分类号：
学科分类号：
摘要：
This study aims to evaluate the serum pro-hepcidin level in β-thalassemia patients, to clarify its relation with serum level of ferritin and to assess the possible role of null polymorphisms of glutathione S-transferase genes, GSTM1 and GSTT1, for susceptibility to β-thalassemia and myocardial siderosis. The serum level of pro-hepcidin was assessed in 31 patients [16 children (52 %) and 15 young adults (48 %)] with β-thalassemia and nine healthy individuals [four children (44 %) and five young adults (56 %)] applying ELISA method. Genotyping for the null polymorphisms of GSTM1 and GSTT1 was performed successfully by multiplex PCR in 17 patients and in 40 healthy individuals, which were enrolled in the case-control study for assessment of the role of these polymorphisms as risk factors for β-thalassemia. The mean serum level of pro-hepcidin in patients did not differ significantly (159.12 ± 70.12 ng/ml) from that in controls (144.64 ± 53.30 ng/ml). We found a significant positive correlation with the serum ferritin (R = 0.371, p = 0.039). In addition, there was an association between the serum pro-hepcidin and the type of chelating therapy. The frequency of GSTT1 null genotypes was significantly higher in patients than in controls (0.29 vs. 0.07, p = 0.025). We observed tendencies for a higher serum ferritin and lower value of ejection fraction of the left ventricle (EFLV) of the patients carrying GSTT1 null genotypes than those with non-null GSTT1 genotypes. The serum levels of pro-hepcidin is not the most precise markers of iron overload and organ dysfunction, but it could be considered as a relatively good alternative of the serum ferritin as an index of iron stores. In addition, we suggest that GSTT1 null genotype could be considered as a predisposing factor for β-thalassemia, myocardial siderosis, and dysfunction in patients with this disease. © 2013 Springer-Verlag London.
引用
收藏
页码：725 / 733
页数：8
相关论文
共 39 条
  • [21] Madani H., Rahimi Z., Manavi-Shad M., Mozafari H., Akramipour R., Vaisi-Raygani A., Rezaei M., Malek-Khosravi S., Shakiba E., Parsian A., Plasma lipids and lipoproteins in children and young adults with major beta-thalassemia from western Iran: influence of genotype, Mol Biol Rep, 38, 4, pp. 2573-2578, (2011)
  • [22] Mak S., Newton G.E., The oxidative stress hypothesis of congestive heart failure: radical thoughts, Chest, 120, 6, pp. 2035-2046, (2001)
  • [23] Matsumoto M., Tsujino T., Lee-Kawabata M., Naito Y., Akahori H., Sakoda T., Ohyanagi M., Tomosugi N., Masuyama T., Iron regulatory hormone hepcidin decreases in chronic heart failure patients with anemia, Circ J, 74, 2, pp. 301-306, (2010)
  • [24] McIlwain C.C., Townsend D.M., Tew K.D., Glutathione S-transferase polymorphisms: cancer incidence and therapy, Oncogene, 25, 11, pp. 1639-1648, (2006)
  • [25] Muncie Jr. H.L., Campbell J., Alpha and beta thalassemia, Am Fam Physician, 80, 4, pp. 339-344, (2009)
  • [26] Nemeth E., Ganz T., Hepcidin and iron-loading anemias, Haematologica, 91, 6, pp. 727-732, (2006)
  • [27] Olivieri N.F., The beta-thalassemias, N Engl J Med, 341, 2, pp. 99-109, (1999)
  • [28] Origa R., Satta S., Matta G., Galanello R., Glutathione S-transferase gene polymorphism and cardiac iron overload in thalassaemia major, Br J Haematol, 142, 1, pp. 143-145, (2008)
  • [29] Papanikolaou G., Tzilianos M., Christakis J.I., Bogdanos D., Tsimirika K., MacFarlane J., Goldberg Y.P., Sakellaropoulos N., Ganz T., Nemeth E., Hepcidin in iron overload disorders, Blood, 105, 10, pp. 4103-4105, (2005)
  • [30] Penkova-Radicheva M., Comparative evaluation of iron overload in patients with chronic liver disease, Trakia J Sci, 9, 1, pp. 10-16, (2011)
1234